Cyclacel Pharmaceuticals, Inc. (CYCC): Price and Financial Metrics


Cyclacel Pharmaceuticals, Inc. (CYCC): $1.21

-0.04 (-3.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYCC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYCC Stock Price Chart Interactive Chart >

Price chart for CYCC

CYCC Price/Volume Stats

Current price $1.21 52-week high $7.45
Prev. close $1.25 52-week low $1.14
Day low $1.19 Volume 196,900
Day high $1.27 Avg. volume 128,059
50-day MA $2.16 Dividend yield N/A
200-day MA $3.76 Market Cap 12.09M

Cyclacel Pharmaceuticals, Inc. (CYCC) Company Bio


Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


CYCC Latest News Stream


Event/Time News Detail
Loading, please wait...

CYCC Latest Social Stream


Loading social stream, please wait...

View Full CYCC Social Stream

Latest CYCC News From Around the Web

Below are the latest news stories about Cyclacel Pharmaceuticals Inc that investors may wish to consider to help them evaluate CYCC as an investment opportunity.

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib – – Expecting Key Data Readouts for Oral Fadraciclib in 2022 – – Planning to Launch Two Registration-Directed Studies for Differentiated Oral PLK1 Inhibitor, CYC140 – BERKELEY HEIGHTS, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biolo

Yahoo | January 6, 2022

Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacels business and the Company will be available for virtual meetings during the conference. In addition, Mr. Rombotis will participate in a Biotech Showcase Workshop, entitled , Outsmarting Cancer: Next Generation Therapies.

GlobeNewswire | December 23, 2021

Vow ASA: Vow strengthens partnership with Respol with agreement to deliver pilot plant using ETIA pyrolysis technology

Vow ASA's (VOW) subsidiary ETIA has received the confirmation from Repsol to deliver a pilot plant to demonstrate the capabilities of VOW Biogreen® systems integration in petrochemical and refineries sites for processing alternative feedstock to generate fuels and materials with low carbon footprint. "We are very excited to provide technology to support Repsol on their ambitious roadmap towards becoming a net zero emissions company. This contract proves the high relevance of our technologies as

Yahoo | December 20, 2021

Vow ASA: Vow bags USD 5.2 million cruise retrofit contract

Vow ASA (“Vow”) has through its subsidiary Scanship been awarded a USD 5.2 million retrofit contract with one of the major cruise line companies. Scanship has entered a USD 5.2 million turnkey contract for the supply and installation of its advanced wastewater purification systems onboard a cruise ship with the capacity to process all wastewater generated from 5000 people. The delivery of process equipment and onboard installation are scheduled to take place during 2022, partly in drydock and du

Yahoo | December 7, 2021

Geode Capital Management LLC Increases Stock Holdings in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)

Geode Capital Management LLC increased its holdings in shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) by 143.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,860 shares of the biotechnology companys stock after buying an additional 29,956 shares during the []

Dakota Financial News | November 29, 2021

Read More 'CYCC' Stories Here

CYCC Price Returns

1-mo -40.10%
3-mo -63.88%
6-mo -67.99%
1-year -83.12%
3-year -90.55%
5-year -98.76%
YTD -68.89%
2021 -50.19%
2020 -41.72%
2019 10.74%
2018 -65.23%
2017 -67.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6301 seconds.